Adaptive Biotechnologies Corp (ADPT) Shares Soar 11.41% on Strong Q1 Earnings

Adaptive Biotechnologies Corp (ADPT) shares surged 11.41% in pre-market trading on May 2, 2025, driven by strong first-quarter earnings and revenue growth.

Adaptive Biotechnologies reported a 34% increase in MRD revenue for the first quarter of 2025, driven by a significant acceleration in clonoSEQ test volume. This growth was attributed to the company's disciplined execution and the scalability of its MRD business. The company's total revenue for the quarter was $52.4 million, representing a 25% increase year-over-year. This performance exceeded market expectations, with earnings and revenue surprises of 28.57% and 21.53%, respectively.

In response to the strong performance, Adaptive Biotechnologies raised its full-year MRD revenue guidance while lowering its operating expenses and cash burn targets. The company remains focused on driving its MRD business to profitability and advancing its Immune Medicine drug discovery programs to deliver long-term value for all stakeholders.